Validation of a drug-based score in advanced urothelial carcinoma treated with pembrolizumab-Reference-Cited by-同舟云学术

Validation of a drug-based score in advanced urothelial carcinoma treated with pembrolizumab

Published:2023-08 Issue:11 Volume:15 Page:827-837
ISSN:1750-743X
Container-title:Immunotherapy
language:en
Short-container-title:Immunotherapy

Author:

Taguchi Satoru¹²^ORCID,Kawai Taketo¹³^ORCID,Buti Sebastiano⁴^ORCID,Bersanelli Melissa⁵^ORCID,Uemura Yukari⁶^ORCID,Kishitani Kenjiro¹,Miyakawa Jimpei¹²,Sugimoto Kazuma²,Nakamura Yu²,Niimi Fusako³,Kaneko Tomoyuki³^ORCID,Kamei Jun⁷^ORCID,Obinata Daisuke⁸,Yamaguchi Kenya⁸,Kakutani Shigenori⁹,Kanazawa Koichiro¹⁰,Sugihara Yuriko¹⁰,Tokunaga Mayuko¹⁰,Akiyama Yoshiyuki¹^ORCID,Yamada Yuta¹^ORCID,Sato Yusuke¹,Yamada Daisuke¹^ORCID,Enomoto Yutaka⁹,Nishimatsu Hiroaki¹⁰,Fujimura Tetsuya⁷,Fukuhara Hiroshi²^ORCID,Nakagawa Tohru³^ORCID,Takahashi Satoru⁸,Kume Haruki¹

Affiliation:

1. Department of Urology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan

2. Department of Urology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka-shi, Tokyo, 181-8611, Japan

3. Department of Urology, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo, 173-8605, Japan

4. Medicine & Surgery Department, University of Parma, Via Gramsci 14, Parma, 43126, Italy

5. Medical Oncology Unit, University Hospital of Parma, Via Gramsci 14, Parma, 43126, Italy

6. Biostatistics Section, Department of Data Science, Center of Clinical Sciences, National Center for Global Health & Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan

7. Department of Urology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke-shi, Tochigi, 329-0498, Japan

8. Department of Urology, Nihon University School of Medicine, 30-1 Oyaguchi Kami-cho, Itabashi-ku, Tokyo, 173-8610, Japan

9. Division of Urology, Mitsui Memorial Hospital, 1 Kanda-izumi-cho, Chiyoda-ku, Tokyo, 101-8643, Japan

10. Department of Urology, The Fraternity Memorial Hospital, 2-1-11 Yokozuna, Sumida-ku, Tokyo, 130-8587, Japan

Abstract

Aim: To validate a ‘drug score’ that stratifies patients receiving immunotherapy based on concomitant medications (antibiotics/proton pump inhibitors/corticosteroids) in urothelial carcinoma (UC). Materials & methods: We assessed oncological outcomes according to the drug score in 242 patients with advanced UC treated with pembrolizumab. Results: The drug score classified patients into three risk groups with significantly different survivals. Heterogeneous treatment effect analyses showed that the primary cancer site (bladder UC [BUC] or upper-tract UC [UTUC]) significantly affected the prognostic capability of the drug score; it significantly correlated with survivals in BUC, while there were no such correlations in UTUC. Conclusion: A drug score was examined in advanced UC treated with pembrolizumab and was validated in BUC but not in UTUC.

Publisher

Future Medicine Ltd

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.futuremedicine.com/doi/pdf/10.2217/imt-2023-0028

Reference32 articles.

1. Improved survival in real‐world patients with advanced urothelial carcinoma: A multicenter propensity score‐matched cohort study comparing a period before the introduction of pembrolizumab (2003–2011) and a more recent period (2016–2020)

2. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

3. The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies

4. Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index

5. Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of Antacids on the Survival of Patients With Metastatic Urothelial Carcinoma Treated With Pembrolizumab;Clinical Genitourinary Cancer;2024-08

2. Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 project;Clinical & Experimental Metastasis;2024-06-08

3. Associations of concomitant medications with immune-related adverse events and survival in advanced cancers treated with immune checkpoint inhibitors: a comprehensive pan-cancer analysis;Journal for ImmunoTherapy of Cancer;2024-03

4. Latest evidence on clinical outcomes and prognostic factors of advanced urothelial carcinoma in the era of immune checkpoint inhibitors: a narrative review;Japanese Journal of Clinical Oncology;2023-12-18

5. Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study;Cancer Immunology, Immunotherapy;2023-09-07